Selinexor and Docetaxel Indicate Promise in KRAS-Mutant NSCLC
In this interview, Mitchell von Itzstein, MD, discusses the challenges of treating KRAS-mutant non-small cell lung cancer (NSCLC), the potential of selinexor in combination with docetaxel, and the need for further research to refine treatment strategies for this patient population....
Cetuximab Boosts KRAS G12C Inhibitors in Lung Cancer
In a groundbreaking study published in 2026, researchers have unveiled a promising therapeutic strategy for combating one of the most aggressive forms of lung cancer. The study focuses on the synergistic effects of combining cetuximab with newly developed KRAS G12C...
UK's NICE Does Not Recommend Lumakras for KRAS G12C-Mutant NSCLC, Asks for More Data
NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Thursday issued a draft guidance that declined to recommend Amgen's KRAS G12C inhibitor Lumakras (sotorasib) for the treatment of previously treated KRAS G12C-mutant locally advanced or...
和誉医药口服小分子KRAS G12D抑制剂ABSK141完成首例患者给药
KRAS是人类癌症中最常见的致癌驱动基因之一，其中G12D为最主要的突变亚型，广泛...
Sintilimab plus anlotinib in later-line treatment of advanced KRAS-mutant NSCLC: a multicenter, retrospective case series
BackgroundPatients with advanced KRAS-mutant non-small cell lung cancer (NSCLC) face a paucity of effective later-line therapies. While combining PD-1 inhibi Abstract Background: Patients with advanced KRAS-mutant non-small cell lung cancer (NSCLC) face a paucity of effective later-line therapies. While combining...
2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC – IASLC
2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC – IASLC RAS(ON) Inhibition: On the Path to Overcoming Therapeutic Resistance and Targeting More Variants in KRAS-Mutated NSCLC. Join this engaging CME symposium exploring the evolving treatment landscape of KRAS-mutated NSCLC....
2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC - IASLC
2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC - IASLC / Alex Spira, cancer, International Association for the Study of Lung Cancer, Kathryn Alex Spira and Kathryn C. Arbour 2026 TTLC Symposia on RAS(ON) Inhibition in KRAS-Mutated NSCLC –...
Cost Advantage of Sotorasib in KRAS G12C–Mutated NSCLC
By: Julia Cipriano, MS, CMPP Posted: Tuesday, February 17, 2026 In a comparison of current efficacy and safety data for KRAS G12C inhibitors, sotorasib demonstrated greater cost-effectiveness than adagrasib for second- and subsequent-line treatment of KRAS G12C–mutated non–small cell lung...